DiaMedica Therapeutics Announces Appointment of Scott Kellen as Chief Financial Officer MINNEAPOLIS, April 05, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “Company”) (TSX-V:DMA) (OTCQB:DMCAF) is pleased to announce the appointment of Mr. Scott Kellen as Chief Financial...

DiaMedica Therapeutics Announces Final Closing of Private Placement MINNEAPOLIS, March 29, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “Company” and “DiaMedica”) (TSX-V:DMA) (OTCQB:DMCAF) is pleased to announce the successful completion of the second...

DiaMedica Therapeutics Announces Closing of Private Placement MINNEAPOLIS, March 20, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “Company”) (TSX-V:DMA) (OTCQB:DMCAF) is pleased to announce the successful completion of the first closing of a...

DiaMedica Announces First Enrollment in its PHASE 2 “REMEDY” TRIAL for Acute Ischemic Stroke DM199 may offer an effective and safe treatment with a significantly longer treatment window (24 hours) compared to the current standard of careREMEDY trial lead by prominent neurologist Dr. Bruce...